All In Biotech

Drug Trial Radar · NCT06012708

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

An Open-label, Dose-escalation and Dose-finding, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 as Combination Therapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Sep 11, 2023

Primary completion

Nov 5, 2024

Study completion Dec 16, 2024

Sponsor

Lead sponsor
New Cancer Cure-Bio Co.,Ltd.Industry
Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of the combination therapy of KN510 and KN713 and determine the MTD and RP2D in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • KN510 60mg/day + KN713 60mg/dayDrug

    Once daily with 28 days (4 weeks) as one cycle.

  • KN510 120mg/day + KN713 60mg/dayDrug

    Once daily with 28 days (4 weeks) as one cycle.

  • KN510 120mg/day + KN713 90mg/dayDrug

    Once daily with 28 days (4 weeks) as one cycle.

  • KN510 120mg/day + KN713 120mg/dayDrug

    Once daily with 28 days (4 weeks) as one cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT(dose limiting toxicity)Time frame: Until 28 days from the first IP administration
  2. AEs(Adverse Events)Time frame: Through study completion, an average of 5 months
  3. Laboratory testsTime frame: Through study completion, an average of 5 months
  4. Vital signsTime frame: Through study completion, an average of 5 months
  5. ECG(Electrocardiogram)Time frame: Through study completion, an average of 5 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Goyang-si, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.